Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
Status:
Terminated
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study is designed to decrease toxicity associated with prior tandem transplant protocols
by reducing the intensity of induction, consolidation and maintenance therapy, while
increasing event-free survival by adding bortezomib (Velcade®), thalidomide, gemcitabine and
carmustine to the transplant regimens to down-regulate the rescue of myeloma cells by the
micro-environment and to prevent DNA repair post high-dose alkylating agent therapy. By
reducing drug resistance, it is hoped that 3-year event-free survival will be increased
significantly when compared to Total Therapy II. Additionally, participants will have the
option of providing biospecimens for a sub-study evaluating gene expression profiling at
specific timepoints to better understand drug-resistance in myeloma, and to determine whether
there are genes or gene products in the resistant population that can be targeted by novel
therapies.